Gelesis Holdings, Inc. (GLS) Research

Gelesis Holdings Inc. is a biopharmaceutical company actively marketing products, dedicated to creating biomimetic solutions that target the underlying causes of obesity and chronic gastrointestinal conditions. Among its key offerings is PLENITY, an oral therapeutic designed for weight management that is non-stimulant and does not enter the bloodstream. The company also provides an additional product for individuals who are overweight or obese, and its robust pipeline features potential treatments for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Established in 2006, Gelesis Holdings Inc. operates from its headquarters in Boston, Massachusetts.

Market snapshot

Symbol
GLS
Price
$0.16
Day change
0.00%
Market cap
$11.6M
P/E ratio
-0.20x
52-week range
0.012-5.67
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Applied Molecular Transport Inc. (AMTI)
  • Axcella Health Inc. (AXLA)
  • Cyclacel Pharmaceuticals, Inc. (CYCC)
  • TuHURA Biosciences, Inc. (HURA)
  • Korro Bio, Inc. (KRRO)
  • Notable Labs, Ltd. (NTBL)
  • ObsEva S.A. (OBSV)
  • Scorpius Holdings, Inc. (SCPX)

Recent insider activity

  • PureTech Health plc — P-Purchase (0 shares) on 2023-09-20
  • PureTech Health plc — P-Purchase (0 shares) on 2023-06-12
  • PureTech Health plc — P-Purchase (43133803 shares) on 2023-05-26
  • PureTech Health plc — P-Purchase (0 shares) on 2023-05-26
  • PureTech Health plc — P-Purchase (192307692 shares) on 2023-05-01

Open Gelesis Holdings, Inc. (GLS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.